Clinical Research
Real Results, Real Relief
We invest in independent clinical research to prove Allergoff works. Our studies demonstrate significant reduction in allergen levels and measurable improvement in patient symptoms.
Our Study
Studying the Effect of Allergoff on House Dust Mite Allergens
A controlled clinical study investigating how Allergoff Spray reduces Der p 1 allergen concentration and improves patient outcomes.
Research Method
Stage 1 (December 2016 – April 2017): 42 participants evaluated for baseline allergen levels and symptom scores.
Stage 2 (November 2017 – April 2018): Expanded to 64 patients with controlled application of Allergoff Spray and comprehensive monitoring.
Proven Effectiveness
What the Research Showed
Significant Symptom Reduction
Average symptom score decreased by 5.4 ± 0.8 points (p<0.05) within 30 days of Allergoff Spray application.
Reduced Medication Use
Patients reported measurable reduction in night symptoms and decreased reliance on asthma and allergy medication.
Strong Correlation
Correlation coefficient R = -0.7 between Der p 1 allergen reduction and improvement in clinical symptoms.
Supporting Research
Backed by Independent Studies
Published research from leading institutions supporting the science behind allergen avoidance and skin barrier protection.
Environmental Control in Pediatric Allergic Disease Prevention
Allergen avoidance is the first line of defense against allergic disease, and while outdoor allergens like pollen are nearly impossible to escape, indoor allergens can be genuinely reduced through practical environmental control. Research backs avoidance as an effective treatment for existing allergic disease, particularly asthma, with (at the time) emerging evidence it can help prevent allergies developing in infants and children altogether.
View on PubMedEffect of Allergen Avoidance in Infancy
RCT showing significant reduction in allergy and eczema using acaricide and physical barrier methods, directly supporting Allergoff's approach.
View on PubMedPrevention of Allergic Disease During Childhood
8-year follow-up of the same trial confirming sustained protection across asthma, eczema, and rhinitis with continued allergen avoidance.
View on PubMedAllergen Barrier Cuts Emergency Hospital Visits by 29%
Children with asthma using allergen barriers had significantly fewer emergency visits (29% vs 42%). Study included 284 children.
View on PubMedMultifaceted Allergen Control Reduces Asthma Symptoms
Allergen reduction decreased indoor allergen levels by up to 51% and reduced daytime asthma symptoms in children. 937 children across 7 cities.
View on NEJMARIA International Guidelines Recommend Allergen Avoidance
The world's leading allergy guideline recommends combined allergen avoidance strategies for managing rhinitis and asthma. Endorsed by WHO.
View on JACIEnvironmental Allergen Reduction Improves Quality of Life
Review of 67 trials found multicomponent allergen reduction strategies improved quality of life and reduced asthma flare-ups.
View on PubMedEmollient Enhancement of Skin Barrier from Birth
RCT demonstrating a 50% reduction in atopic dermatitis risk using daily emollient application from birth.
View on PubMedEarly Intervention of Atopic Dermatitis as a Preventive Strategy
Backs the connection between skin barrier repair and preventing the progression of atopic dermatitis into food allergies.
View on PubMedEarlier Aggressive Eczema Treatment Reduces Food Allergies
Shows that treating eczema early and proactively in infants resulted in fewer food allergies at 2 years of age.
View on PubMedThe Data
Clinical Results
Visual representation of allergen concentration changes and their correlation with patient symptom improvements.
Der p 1 vs Symptom Improvement
Der p 1 vs Medication Reduction
Download the Full Report
Access the complete clinical trial summary with detailed methodology, data tables, and statistical analysis.
Download Report (PDF)The Conclusion
Allergoff Spray Delivers Measurable Clinical Results
The clinical study confirms that Allergoff Spray effectively reduces Der p 1 allergen concentration in household environments, leading to statistically significant improvement in patient symptoms within 30 days of application.